PM
IMRX icon

Prosight Management’s Immuneering IMRX Stock Holding History

Prosight Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$184K Sell
36,861
-86,548
-70% -$438K 0.03% 36
2026
Q1 		$650K Buy
+123,409
New +$633K 0.11% 42
2024
Q4 		– Sell
-190,000
Closed -$473K – 41
2024
Q3 		$473K Sell
190,000
-360,000
-65% -$524K 0.12% 43
2024
Q2 		$704K Buy
+550,000
New +$904K 0.21% 44

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Prosight Management's IMRX Position: Q2 2026 in Review

Prosight Management reduced its Immuneering (IMRX) stake by 70% in Q2 2026, selling an estimated $438K and leaving 36,861 shares worth $184K. The position accounts for 0.03% of the portfolio, ranked #36.

Prosight Management first reported a position in IMRX in Q2 2024 and has held it in 4 quarters since. The position peaked at $704K in Q2 2024. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Prosight Management held 36,861 shares of Immuneering worth $184K as of Q2 2026.
  • Prosight Management sold 86,548 Immuneering shares in Q2 2026, an estimated $438K.
  • Immuneering made up 0.03% of Prosight Management's portfolio in Q2 2026, its #36 holding.
  • Prosight Management first reported a position in Immuneering in Q2 2024 and has held it in 4 quarters since.
  • Prosight Management's Immuneering position peaked at $704K in Q2 2024.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.